Welcome to our dedicated page for STEMTECH CORPORATION SEC filings (Ticker: STEK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stemtech Corporation’s stem-cell nutrition products and direct-sales model make its disclosures uniquely rich in distributor metrics, R&D spending and patent updates. If you have ever asked, “Where can I find Stemtech’s quarterly earnings report 10-Q filing?” or “How do I track Stemtech insider trading Form 4 transactions?”, you are in the right place.
Stock Titan’s AI reads every page the moment it hits EDGAR, then delivers concise highlights—no more searching through 300-page PDFs. Our platform pinpoints:
- Revenue by region and Independent Business Partner turnover tucked inside the annual report—Stemtech annual report 10-K simplified.
- Sequential sales trends and cash-flow notes from each Stemtech quarterly earnings report 10-Q filing.
- Real-time alerts for Stemtech Form 4 insider transactions so you can see executive stock moves before the market reacts.
- Material announcements such as product launches or distribution agreements in Stemtech 8-K material events explained.
- Board pay packages within the Stemtech proxy statement executive compensation.
Every document comes with an AI-powered summary that explains complex accounting and “stemceutical” science in plain language—perfect for investors comparing margins or analysts monitoring R&D efficiency. Need the raw filing? Download it instantly, or skim our AI annotations for the key numbers.
Whether you’re monitoring Stemtech insider trading Form 4 transactions real-time, seeking an earnings report filing analysis, or simply understanding Stemtech SEC documents with AI, Stock Titan transforms dense disclosures into actionable insight—updated the moment Stemtech (STEK) hits “submit.”
Stemtech Corporation (STEK) reported another loss-making quarter and raised going concern doubts in its Q3 2025 report. For the quarter ended September 30, 2025, net sales were $852,300, down from $1,031,630 a year earlier, as the company shifted away from lower-margin volume toward core markets. Despite lower revenue, cost controls helped reduce operating loss to $339,217 from $716,470, and net loss narrowed to $812,541 from $1,171,405.
For the nine months, sales fell to $2,418,271 from $3,740,000, but net loss improved to $2,567,547 from $3,376,121 as operating expenses declined by about $1.3 million. The balance sheet remains strained: assets were $3,755,801 against current liabilities of $10,301,779, resulting in a stockholders’ deficit of $6,545,978 and a working capital deficit of about $9.2 million.
Management explicitly concluded that substantial doubt about the company’s ability to continue as a going concern is not alleviated, citing recurring losses, negative operating cash flow, dependence on external financing, and defaults under certain Merchant Cash Advance agreements now in litigation. Stemtech is pursuing private equity raises, a proposed convertible debt facility, cost cuts, and international joint ventures to improve liquidity, but these plans are not yet committed or realized.
Stemtech Corporation filed a Form 12b-25 (NT 10-Q) notifying a late filing of its quarterly report for the period ended September 30, 2025. The company cites delays in preparing its quarterly financial statements as the reason.
The notification lists Charles Arnold, CEO, as the signatory and provides a company contact at (954) 715-6000. The notice was signed on November 14, 2025.
FAQ
What is the current stock price of STEMTECH CORPORATION (STEK)?
What is the market cap of STEMTECH CORPORATION (STEK)?
